US Stock MarketDetailed Quotes
KPTI Karyopharm Therapeutics
- 0.990
- +0.150+17.81%
Close Oct 31 16:00 ET
- 1.020
- +0.030+3.05%
Post 19:52 ET
123.41MMarket Cap-868P/E (TTM)
1.130High0.870Low8.39MVolume0.900Open0.840Pre Close8.34MTurnover7.40%Turnover RatioLossP/E (Static)124.68MShares1.95052wk High-0.93P/B112.13MFloat Cap0.61752wk Low--Dividend TTM113.28MShs Float49.005Historical High--Div YieldTTM30.93%Amplitude0.617Historical Low0.994Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Karyopharm Therapeutics Stock Forum
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics (Nasdaq: KPTI)announced a change in co-primary endpoint for its Phase 3 SENTRY Trial in myelofibrosis, replacing TSS50 with Absolute Total Symptom Score (Abs-TSS) following FDA feedback. The trial's sample size will increase to approximately 350 patients, with top-line data expected in 2H 2025.
Phase 1 trial data showed pr...
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 Sentry Trial in Myelofibrosis
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet